\
&
Contact us
\
&
Contact us
Published on | 44 minutes ago
ProgrammesThe Testing and Experimentation Facility for Health AI and Robotics (TEF-Health) has opened a call offering SMEs discounted access to novel validation and experimentation services for health AI and robotic solutions. Through TEF-Health, SMEs can work with European research centres, hospitals, universities and certification bodies to test AI and robotics solutions using high-quality data and real clinical environments, helping prepare products for market entry.
More information on the call and its requirements can be found on the dedicated website.
The call stays open until the capacity of the service providers is reached, and closes at the latest at the end of the TEF-Health project funding period on 31 December 2027.
Background: TEF-Health is a Digital Europe project coordinated by Charité Universitätsmedizin Berlin, Germany and comprises 52 partners from 9 European Union countries — each forming a so-called Node. The project is co-financed by national funding provided by Belgium, France, Germany, Portugal, Slovakia and Sweden.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
